Kane Biotech Inc. announced that, it has appointed Rashieda (Rivka) Gluck to the Corporation’s Board of Directors. With over 20 years of experience in the global pharmaceutical, biotechnology, and life science industries, Ms. Gluck’s career has spanned all levels and functions in clinical development. Currently, Ms. Gluck is on the executive management team of Aurinia Pharmaceuticals, developing and implementing their overall corporate strategy. She also leads all clinical operations for their lead drug, voclosporin. Prior to that, Ms. Gluck has held management-level, clinical operations roles at innovative companies including Qu Biologics, Vifor Pharma, Novartis, and GlaxoSmithKline, among others. Ms. Gluck currently serves as Senior Vice President of Global Clinical Operations at Aurinia Pharmaceuticals Inc. since February 2018 and has also served as its Vice President of Clinical Operations since January 1, 2016.